Cargando…

Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice

BACKGROUND: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an expanded CAG repeat in the HD gene. Both excitotoxicity and oxidative stress have been proposed to play important roles in the pathogenesis of HD. Since no effective treatment is available, this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil, Joana MAC, Leist, Marcel, Popovic, Natalija, Brundin, Patrik, Petersén, Åsa
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC434499/ https://www.ncbi.nlm.nih.gov/pubmed/15134587 http://dx.doi.org/10.1186/1471-2202-5-17

Ejemplares similares

Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice
por: Petersén, Åsa, et al.
Publicado: (2005)

Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
por: Kittur, Farooqahmed S., et al.
Publicado: (2019)

Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice
por: Dickson, Elna, et al.
Publicado: (2022)

Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice
por: Soylu-Kucharz, Rana, et al.
Publicado: (2017)

IKKβ slows Huntington’s disease progression in R6/1 mice
por: Ochaba, Joseph, et al.
Publicado: (2019)

Continuous and Periodic Expansion of CAG Repeats in Huntington's Disease R6/1 Mice
por: Møllersen, Linda, et al.
Publicado: (2010)

The Role of Hypothalamic Pathology for Non-Motor Features of Huntington’s Disease
por: Cheong, Rachel Y., et al.
Publicado: (2019)

Effects of Anthocyanins on CAG Repeat Instability and Behaviour in Huntington’s Disease R6/1 Mice
por: Møllersen, Linda, et al.
Publicado: (2016)

Age-Dependent Degradation of Locomotion Encoding in Huntington’s Disease R6/2 Model Mice
por: Yamin, Hagar G., et al.
Publicado: (2021)

Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease
por: Henningsen, Jo B., et al.
Publicado: (2021)

Oxytocin in Huntington’s disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia
por: Bergh, Sofia, et al.
Publicado: (2022)

Maintenance of Basal Levels of Autophagy in Huntington’s Disease Mouse Models Displaying Metabolic Dysfunction
por: Baldo, Barbara, et al.
Publicado: (2013)

Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice
por: Reidling, Jack C., et al.
Publicado: (2017)

Sleep Physiology Alterations Precede Plethoric Phenotypic Changes in R6/1 Huntington’s Disease Mice
por: Lebreton, Fanny, et al.
Publicado: (2015)

iNKT Cell Activation Exacerbates the Development of Huntington's Disease in R6/2 Transgenic Mice
por: Park, Hyun Jung, et al.
Publicado: (2019)

A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice
por: Heath, Christopher J., et al.
Publicado: (2019)

Striatal Pre-Enkephalin Overexpression Improves Huntington’s Disease Symptoms in the R6/2 Mouse Model of Huntington’s Disease
por: Bissonnette, Stéphanie, et al.
Publicado: (2013)

IKKβ signaling mediates metabolic changes in the hypothalamus of a Huntington disease mouse model
por: Soylu-Kucharz, Rana, et al.
Publicado: (2022)

New Avenues for the Treatment of Huntington’s Disease
por: Kim, Amy, et al.
Publicado: (2021)

Huntington's disease: of mice and men
por: Yhnel, Emma
Publicado: (2017)

Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntington’s disease
por: Soylu-Kucharz, Rana, et al.
Publicado: (2016)

Analysis of LINE1 Retrotransposons in Huntington’s Disease
por: Floreani, Lavinia, et al.
Publicado: (2022)

Repeated immune activation with low-dose lipopolysaccharide attenuates the severity of Huntington's disease in R6/2 transgenic mice
por: Lee, Sung Won, et al.
Publicado: (2018)

Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington’s disease transgenic R6/2 (160 CAG) mice
por: Di Pardo, A., et al.
Publicado: (2017)

Beyond Motor Deficits: Environmental Enrichment Mitigates Huntington’s Disease Effects in YAC128 Mice
por: Plácido, Evelini, et al.
Publicado: (2023)

Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls
por: Bacelis, Jonas, et al.
Publicado: (2021)

Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington’s Disease
por: Paldino, Emanuela, et al.
Publicado: (2019)

Quantification of Huntington’s Disease Related Markers in the R6/2 Mouse Model
por: Etxeberria-Rekalde, Estibaliz, et al.
Publicado: (2021)

Multiplatform metabolomic analysis of the R6/2 mouse model of Huntington’s disease
por: Hashimoto, Masayo, et al.
Publicado: (2021)

Effects of mutant huntingtin inactivation on Huntington disease‐related behaviours in the BACHD mouse model
por: Cheong, Rachel Y., et al.
Publicado: (2021)

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
por: Valdeolivas, Sara, et al.
Publicado: (2017)

Myelinosome Organelles in the Retina of R6/1 Huntington Disease (HD) Mice: Ubiquitous Distribution and Possible Role in Disease Spreading
por: Yefimova, Marina G., et al.
Publicado: (2021)

Supplemental Treatment for Huntington’s Disease with miR-132 that Is Deficient in Huntington’s Disease Brain
por: Fukuoka, Masashi, et al.
Publicado: (2018)

Progressive Cl(−) channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington’s mice
por: Miranda, Daniel R., et al.
Publicado: (2017)

Tetrabenazine is neuroprotective in Huntington's disease mice
por: Wang, Hongyu, et al.
Publicado: (2010)

Microarray profiling of hypothalamic gene expression changes in Huntington’s disease mouse models
por: Dickson, Elna, et al.
Publicado: (2022)

Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2018)

Effects of Deletion of Mutant Huntingtin in Steroidogenic Factor 1 Neurons on the Psychiatric and Metabolic Phenotype in the BACHD Mouse Model of Huntington Disease
por: Baldo, Barbara, et al.
Publicado: (2014)

PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington’s Disease
por: Cardinale, Antonella, et al.
Publicado: (2015)

White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington’s Disease
por: McCourt, Andrew C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aeesmp94t7pd9blm4fujj801bu